Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

612.88
Delayed Data
As of Aug 12
 +14.02 / +2.34%
Today’s Change
271.37
Today|||52-Week Range
664.64
+63.23%
Year-to-Date
FDA accepts Regeneron application for evinacumab for inherited cholesterol disorder
Aug 12 / Seeking Alpha - Paid Partner Content
Regeneron lands BARDA contract for Ebola cocktail
Jul 29 / Seeking Alpha - Paid Partner Content
Merck to Begin Pivotal COVID-19 Antiviral Studies in September
Jul 31 / MotleyFool.com - Paid Partner Content
Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players
Jul 28 / Seeking Alpha - Paid Partner Content
Regeneron teams up with BioNTech in melanoma
Jul 31 / Seeking Alpha - Paid Partner Content
Biotech Bonanza - Second Half Outlook
Jul 28 / Seeking Alpha - Paid Partner Content

Today’s Trading

Previous close598.86
Today’s open599.89
Day’s range599.89 - 617.00
Volume24,449
Average volume (3 months)1,182,350
Market cap$66.0B
Data as of 6:00pm ET, 08/12/2020

Growth & Valuation

Earnings growth (last year)-14.46%
Earnings growth (this year)+22.85%
Earnings growth (next 5 years)+12.50%
Revenue growth (last year)+17.18%
P/E ratio23.8
Price/Sales5.47
Price/Book6.17

Competitors

----
VRTXVertex Pharmaceutica...+9.12+3.48%
----
TAKTakeda Pharmaceutica...+0.20+1.08%
Data as of 4:05pm ET, 08/12/2020

Financials

Next reporting dateNovember 4, 2020
EPS forecast (this quarter)$7.29
Annual revenue (last year)$7.9B
Annual profit (last year)$2.1B
Net profit margin26.91%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Tarrytown, New York

Forecasts